Please use this identifier to cite or link to this item:
|Title:||Reduction in Staphylococcus aureus bacteraemia rates in patients receiving haemodialysis following alteration of skin antisepsis procedures.|
|Authors:||Stewart, B J|
Perry, G J
Tong, S Y C
|Affiliation:||Department of Nephrology, Royal Darwin Hospital, Darwin, Australia; Division of Medical Sciences, University of Oxford, Oxford, UK..|
Infection Prevention and Management Unit, Royal Darwin Hospital, Darwin, Australia; Infection Control Unit, Queen Elizabeth II Hospital, Brisbane, Australia..
Department of Nephrology, Royal Darwin Hospital, Darwin, Australia; Department of Nephrology, Royal Perth Hospital, Perth, Australia..
Menzies School of Health Research, Darwin, Australia. Electronic address: firstname.lastname@example.org..
|Citation:||The Journal of hospital infection 2016-02; 92(2): 191-3|
|Abstract:||This study examined all cases of Staphylococcus aureus bacteraemia (SAB) in the haemodialysis cohort at the Royal Darwin Hospital, Australia over a seven-year period. Midway through this period, antisepsis for arteriovenous fistulae (AVF) and central venous catheters (CVC) changed from 0.5% chlorhexidine solution to 2% chlorhexidine solution. Rates of SAB episodes were calculated using registry data. Trends in SAB over time were analysed using an interrupted regression analysis. Following the change to 2% chlorhexidine, average SAB rates decreased by 68%, and it is estimated that 0.111 cases of SAB/patient-year were prevented. CVC-related SAB rates remained low throughout. These results support the use of 2% chlorhexidine in skin antisepsis for patients with AVF.|
Research Support, Non-U.S. Gov't
Central venous catheter
Anti-Infective Agents, Local
|Appears in Collections:||NT Health digital library|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.